Skip to content

Study · Non-randomized trial · n = 194 · 2015

6 results

Ultrasound findings of mild neonatal periventricular-intraventricular hemorrhage after different treatments.

Wang S, Liao C, Liang S, Zhong D, Liu J, Li Z

International journal of clinical and experimental medicine15 Apr 2015

PMID26131081 (opens in a new tab)PMCIDPMC4484013 (opens in a new tab)PepBankPUB-26131081
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In newborns with mild PIVH, GDDS evaluation did not differ among groups, including Cerebrolysin.

    In plain wordsIn newborns with mild PIVH, developmental evaluation did not differ among groups, including Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeGDDS evaluation
    Study

    n = 194

    Comparator
    Other treatment groups
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    P value for GDDS evaluation among three treatment groups
    > 0.05 unitless
    GDDS evaluation among three treatment groups

    Source sentences

    Summary
    GDDS evaluation showed no significant difference among three groups (P>0.05), and all the patients recovered completely.
    1 context sentence
    Summary · context
    A total of 194 newborns with grade I-II PIVH were recruited, and findings of cranial ultrasound examination before and 1 month after birth were included for analysis.
  2. 02HumanNon-randomized trialEfficacy outcome

    In newborns with grade I PIVH, echo intensity did not differ among three groups, including Cerebrolysin.

    In plain wordsIn newborns with grade I PIVH, echo intensity did not differ among groups, including Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeEcho intensity in grade I PIVH
    Study

    n: not reported in source

    Comparator
    Other treatment groups
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    P value for echo intensity among three treatment groups
    > 0.05
    Across three treatment groups in grade I PIVH

    Source sentences

    Summary
    There was no significant difference in the echo intensity among three groups of grade I PIVH patients (P>0.05).
    1 context sentence
    Summary · context
    A total of 194 newborns with grade I-II PIVH were recruited, and findings of cranial ultrasound examination before and 1 month after birth were included for analysis.
  3. 03HumanNon-randomized trialEfficacy outcome

    In newborns with grade II PIVH, Cerebrolysin had lower therapeutic efficacy on echo intensity than ganglioside, which ranked best among groups.

    In plain wordsIn newborns with grade II PIVH, Cerebrolysin had lower therapeutic efficacy on echo intensity than ganglioside.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseEcho intensity in grade II PIVH
    Study

    n: not reported in source

    Comparator
    Ganglioside
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    P value for echo intensity among three treatment groups
    < 0.05
    Across three treatment groups in grade II PIVH

    Source sentences

    Summary
    There was significant difference in the echo intensity among three groups of grade II PIVH patients, and the ganglioside had the best therapeutic efficacy (P<0.05).
    1 context sentence
    Summary · context
    A total of 194 newborns with grade I-II PIVH were recruited, and findings of cranial ultrasound examination before and 1 month after birth were included for analysis.
  4. 04HumanNon-randomized trialEfficacy outcome

    In newborns with grade I PIVH, lesion area change did not differ among three groups, including Cerebrolysin.

    In plain wordsIn newborns with grade I PIVH, lesion area change did not differ among groups, including Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeLesion area change in grade I PIVH
    Study

    n: not reported in source

    Comparator
    Other treatment groups
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    P value for Lesion area change among three grade I PIVH treatment groups
    > 0.05 unitless
    Lesion area change among three grade I PIVH treatment groups

    Source sentences

    Summary
    No significant difference was observed in the area change among three groups of grade I PIVH patients (P>0.05).
    1 context sentence
    Summary · context
    A total of 194 newborns with grade I-II PIVH were recruited, and findings of cranial ultrasound examination before and 1 month after birth were included for analysis.
  5. 05HumanNon-randomized trialEfficacy outcome

    In newborns with grade II PIVH, ganglioside showed better efficacy on lesion area change than Cerebrolysin.

    In plain wordsIn newborns with grade II PIVH, Cerebrolysin had lower efficacy on lesion area change than ganglioside.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseLesion area change in grade II PIVH versus ganglioside
    Study

    n: not reported in source

    Comparator
    Ganglioside
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    P value for Lesion area change: ganglioside versus cerebrolysin and control in grade II PIVH
    < 0.05 unitless
    Lesion area change: ganglioside versus cerebrolysin and control in grade II PIVH

    Source sentences

    Summary
    However, significant difference was observed in the area change among three groups of grade II PIVH patients, and ganglioside had a better efficacy than cerebrolysin and control agent (P<0.05)
    1 context sentence
    Summary · context
    A total of 194 newborns with grade I-II PIVH were recruited, and findings of cranial ultrasound examination before and 1 month after birth were included for analysis.
  6. 06HumanNon-randomized trialEfficacy outcome

    In newborns with grade II PIVH, lesion area change did not differ between Cerebrolysin and control.

    In plain wordsIn newborns with grade II PIVH, lesion area change did not differ between Cerebrolysin and control.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeLesion area change in grade II PIVH versus control
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    P value for Lesion area change: cerebrolysin versus control in grade II PIVH
    > 0.05 unitless
    Lesion area change: cerebrolysin versus control in grade II PIVH

    Source sentences

    Summary
    However, significant difference was observed in the area change among three groups of grade II PIVH patients, and ganglioside had a better efficacy than cerebrolysin and control agent (P0.05).
    1 context sentence
    Summary · context
    A total of 194 newborns with grade I-II PIVH were recruited, and findings of cranial ultrasound examination before and 1 month after birth were included for analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.